Ado-trastuzumab emtansine Alternatives Compared
Ado-trastuzumab emtansine | Kisqali | Alpelisib |
|
---|
Ado-trastuzumab emtansine | Kisqali (ribociclib) | Alpelisib |
|
---|---|---|---|
Prescription only
Prescribed for Breast Cancer - Metastatic, Breast Cancer. ado-trastuzumab emtansine may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Breast Cancer - Metastatic, Breast Cancer. Kisqali may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for PIK3CA-Related Overgrowth Spectrum, Breast Cancer, Breast Cancer - Male. alpelisib may also be used for purposes not listed in this medication guide. |
|
More about Ado-trastuzumab emtansine | More about Kisqali (ribociclib) | More about Alpelisib | |
Ratings & Reviews | |||
Be the first to share your experience with this drug. |
Kisqali has an average rating of 8.5 out of 10 from a total of 25 ratings on Drugs.com. 83% of reviewers reported a positive effect, while 4% reported a negative effect. |
Alpelisib has an average rating of 6.3 out of 10 from a total of 3 ratings on Drugs.com. 67% of reviewers reported a positive effect, while 33% reported a negative effect. |
|
Drug Class | |||
Side Effects | |||
See also: ado-trastuzumab emtansine side effects in more detail. |
See also: Kisqali side effects in more detail. |
See also: alpelisib side effects in more detail. |
|
Generic Availability | |||
N/A |
N/A |
||
Pricing and Coupons * Prices are without insurance | |||
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
|
Dosage Form(s) Available | |||
N/A |
|
N/A |
|
Brand Names | |||
Kadcyla |
N/A |
Piqray, Vijoice | |
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | |||
96 hours |
54.7 hours |
9 hours |
|
CSA Schedule ** View glossary of terms | |||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
|
Pregnancy Category | |||
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
|
Drug Interactions | |||
A total of 257 drugs are known to interact with ado-trastuzumab emtansine:
|
A total of 708 drugs are known to interact with Kisqali:
|
A total of 313 drugs are known to interact with alpelisib:
|
|
Alcohol/Food/Lifestyle Interactions | |||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
|
|
Disease Interactions | |||
First Approval Date | |||
N/A |
March 13, 2017 |
May 24, 2019 |
|
WADA Class View World Anti-Doping Agency classifications. | |||
N/A |
N/A |
N/A |
|
More Information | |||
Patient resources | |||
Professional Resources | |||
Related Treatment Guide | |||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.